Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure

This publication has 28 references indexed in Scilit:

• Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea
  JACC, 2002
• Effect of Carvedilol on Survival in Severe Chronic Heart Failure
  New England Journal of Medicine, 2001
• Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study
  JACC, 1998
• Potentiation of Natriuretic Peptide Action by the β -Adrenergic Blocker Carvedilol in Hypertensive Rats: A New Antihypertensive Mechanism¹
  Endocrinology, 1998
• The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
  New England Journal of Medicine, 1996
• Chronic Effect of .BETA.-Adrenoceptor Blockade on Plasma Levels of Brain Natriuretic Peptide during Exercise in Essential Hypertension.
  Hypertension Research, 1996
• Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
  Circulation, 1994
• Endothelin in human congestive heart failure.
  Circulation, 1994
• Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
  The Lancet, 1993
• Effect of beta-adrenergic receptor blockade on atrial natriuretic peptide in essential hypertension.
  Hypertension, 1987